Heather Ramous
Acute Care · Safety Harbor, FLNPI 1326547365
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Boehringer Ingelheim at 45.4% of the total. 2025 is the largest year on record at $16,795, 4.9 times the $3,411 reported in 2021. Among acute care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 925 payments — averaging $41.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$17K
- AstraZeneca$4K
- GSK$2K
- Sanofi$2K
- Insmed, Inc.$1K
- Actelion Pharmaceuticals US, Inc.$1K
- plus $10K from 33 others
What the payments were for
- Consulting fees$6,58417%
- Speaking & faculty fees$4,24011%
- Travel & lodging$5,72615%
- Food & beverage$21,21656%
- Education$4211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 127 | $17,323 |
| AstraZeneca(2 entities) | 128 | $4,029 |
| GSK | 118 | $2,327 |
| Sanofi | 27 | $2,207 |
| Insmed, Inc. | 38 | $1,405 |
| Actelion Pharmaceuticals US, Inc. | 74 | $1,339 |
| Takeda Pharmaceuticals U.S.A., Inc. | 46 | $1,110 |
| Regeneron Healthcare Solutions, Inc. | 30 | $894 |
| Electromed, Inc. | 69 | $865 |
| United Therapeutics Corporation | 29 | $705 |
| Amgen | 43 | $700 |
| Mallinckrodt Hospital Products Inc. | 22 | $665 |
| Bayer | 21 | $576 |
| Grifols USA, LLC | 14 | $532 |
| Baxter Healthcare | 15 | $360 |
| AbbVie | 16 | $338 |
| Johnson & Johnson(2 entities) | 17 | $312 |
| Shionogi Inc | 7 | $283 |
| Novartis | 12 | $268 |
| Pulmonx Corporation | 6 | $252 |
| Merck | 8 | $230 |
| Verona Pharma, Inc. | 8 | $208 |
| Inspire Medical Systems, Inc. | 4 | $183 |
| Inogen, Inc. | 11 | $176 |
| Covis Pharma GmbH | 4 | $110 |
| Vapotherm Inc | 5 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Advanced Respiratory, Inc | 4 | $94 |
| Philips North America LLC | 4 | $93 |
| Mylan Specialty L.p. | 3 | $92 |
| Teva Pharmaceuticals USA, Inc. | 3 | $74 |
| Gilead | 3 | $62 |
| Abiomed | 1 | $51 |
| Shield Therapeutics Inc | 2 | $37 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Ambu Inc. | 1 | $19 |
| Liquidia Technologies, Inc. | 1 | $17 |
| Resmed Corp | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$7,568
- BREZTRI$889
- FASENRA$859
- TEZSPIRE$495
- Prolastin-C Liquid$221
- FARXIGA$210
- CHARTIS CATHETER$161
- ZEPHYR DELIVERY CATHETER$161
- ZEPHYR ENDOBRONCHIAL VALVE$161
- PULMONX CHARTIS TABLET CONSOLE$161
- SMARTVEST$124
- AIRSUPRA$107
- DUPIXENT$106
How this compares
$38,187 in reported general payments places this provider in the 95th percentile of 1,150 acute care providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 344 | $289,345 |
| OpsumitMacitentan | 13 | $155,300 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 126 | $122,594 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 116 | $63,739 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 78 | $49,377 |
| Breo ElliptaFluticasone/Vilanterol | 81 | $43,462 |
| Spiriva RespimatTiotropium Bromide | 53 | $39,524 |
| SymbicortBudesonide/Formoterol Fumarate | 74 | $26,678 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 26 | $13,490 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 365 | $10,127 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $7,970 |
| Spiriva HandihalerTiotropium Bromide | 15 | $7,499 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 24 | $6,793 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $5,976 |
| Wixela InhubFluticasone Propion/Salmeterol | 22 | $5,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $2,327 | $396,546541 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $4,029 | $162,762226 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,339 | $155,30013 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $17,323 | $96,871148 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,150 acute care providers in Florida.
Other acute care in Safety Harbor
- Melisa WilsonOrlando$214K
- Amanda PeacockJacksonville$81K
- Katrina RileyTampa$66K
- Diane GrayLake Mary$49K
- Melanie WeresJacksonville$37K
- Jayne JaramilloJacksonville$27K
- Melissa HamiltonTampa$23K
- Kimberly GrantAltamonte Springs$20K
- Julie ElliottWinter Haven$17K
- Reynier AvonAventura$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.